(EXPO) Exponent - Overview
Stock: Consulting, Analysis, Testing, Risk
Dividends
| Dividend Yield | 1.57% |
| Yield on Cost 5y | 1.35% |
| Yield CAGR 5y | 10.67% |
| Payout Consistency | 100.0% |
| Payout Ratio | 58.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 28.3% |
| Relative Tail Risk | -10.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.48 |
| Alpha | -22.73 |
| Character TTM | |
|---|---|
| Beta | 0.618 |
| Beta Downside | 0.238 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.55% |
| CAGR/Max DD | -0.20 |
Description: EXPO Exponent January 11, 2026
Exponent, Inc. (NASDAQ: EXPO) is a science- and engineering-consulting firm that serves a broad spectrum of industries through two operating segments: Engineering & Other Scientific, and Environmental & Health.
The Engineering segment delivers expertise in biomechanics, biomedical engineering, civil/structural engineering, data science, electrical/computer engineering, materials science, mechanical engineering, polymer chemistry, thermal sciences, and vehicle engineering. The Environmental & Health segment focuses on chemical regulation, food safety, ecological and biological sciences, environmental and earth sciences, and health sciences, plus proactive/reactive product safety, litigation support, and regulatory services.
Key customers span chemicals, construction, consumer products, energy, food & beverage, government, life sciences, insurance, manufacturing, technology, industrial equipment, and transportation, reflecting the firm’s diversified revenue base.
Recent performance highlights (FY 2023) include revenue of approximately $1.0 billion, an operating margin near 13 %, and a backlog exceeding $1.2 billion, indicating strong demand for consulting services amid heightened ESG compliance and rising product-liability litigation. The sector is further buoyed by increased regulatory scrutiny in chemicals and food safety, which drives steady growth for firms with deep technical expertise.
For a deeper quantitative assessment, you might explore ValueRay’s analyst notes on EXPO.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 106.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -3.94 > 1.0 |
| NWC/Revenue: 57.43% < 20% (prev 50.80%; Δ 6.63% < -1%) |
| CFO/TA 0.17 > 3% & CFO 132.2m > Net Income 106.0m |
| Net Debt (-139.1m) to EBITDA (144.9m): -0.96 < 3 |
| Current Ratio: 2.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.6m) vs 12m ago -2.03% < -2% |
| Gross Margin: 45.43% > 18% (prev 0.42%; Δ 4501 % > 0.5%) |
| Asset Turnover: 55.90% > 50% (prev 71.86%; Δ -15.95% > 0%) |
| Interest Coverage Ratio: -3.32 > 6 (EBITDA TTM 144.9m / Interest Expense TTM -34.1m) |
Altman Z'' 7.69
| A: 0.32 (Total Current Assets 427.6m - Total Current Liabilities 178.0m) / Total Assets 777.5m |
| B: 0.86 (Retained Earnings 668.4m / Total Assets 777.5m) |
| C: 0.15 (EBIT TTM 113.2m / Avg Total Assets 777.4m) |
| D: 1.72 (Book Value of Equity 666.2m / Total Liabilities 387.2m) |
| Altman-Z'' Score: 7.69 = AAA |
Beneish M -2.85
| DSRI: 1.45 (Receivables 181.5m/161.4m, Revenue 434.6m/558.5m) |
| GMI: 0.93 (GM 45.43% / 42.15%) |
| AQI: 1.12 (AQ_t 0.26 / AQ_t-1 0.23) |
| SGI: 0.78 (Revenue 434.6m / 558.5m) |
| TATA: -0.03 (NI 106.0m - CFO 132.2m) / TA 777.5m) |
| Beneish M-Score: -2.85 (Cap -4..+1) = A |
What is the price of EXPO shares?
Over the past week, the price has changed by +6.35%, over one month by +5.03%, over three months by +11.11% and over the past year by -12.42%.
Is EXPO a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EXPO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 90.3 | 15.3% |
| Analysts Target Price | 90.3 | 15.3% |
| ValueRay Target Price | 81 | 3.4% |
EXPO Fundamental Data Overview February 09, 2026
P/E Forward = 35.8423
P/S = 7.5071
P/B = 9.8806
P/EG = 3.14
Revenue TTM = 434.6m USD
EBIT TTM = 113.2m USD
EBITDA TTM = 144.9m USD
Long Term Debt = 75.9m USD (estimated: total debt 82.8m - short term 6.89m)
Short Term Debt = 6.89m USD (from shortTermDebt, last quarter)
Debt = 82.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -139.1m USD (from netDebt column, last quarter)
Enterprise Value = 3.89b USD (4.03b + Debt 82.8m - CCE 221.9m)
Interest Coverage Ratio = -3.32 (Ebit TTM 113.2m / Interest Expense TTM -34.1m)
EV/FCF = 31.65x (Enterprise Value 3.89b / FCF TTM 122.9m)
FCF Yield = 3.16% (FCF TTM 122.9m / Enterprise Value 3.89b)
FCF Margin = 28.28% (FCF TTM 122.9m / Revenue TTM 434.6m)
Net Margin = 24.39% (Net Income TTM 106.0m / Revenue TTM 434.6m)
Gross Margin = 45.43% ((Revenue TTM 434.6m - Cost of Revenue TTM 237.1m) / Revenue TTM)
Gross Margin QoQ = none% (prev 24.94%)
Tobins Q-Ratio = 5.00 (Enterprise Value 3.89b / Total Assets 777.5m)
Interest Expense / Debt = 7.75% (Interest Expense 6.42m / Debt 82.8m)
Taxrate = 27.39% (9.34m / 34.1m)
NOPAT = 82.2m (EBIT 113.2m * (1 - 27.39%))
Current Ratio = 2.40 (Total Current Assets 427.6m / Total Current Liabilities 178.0m)
Debt / Equity = 0.21 (Debt 82.8m / totalStockholderEquity, last quarter 390.3m)
Debt / EBITDA = -0.96 (Net Debt -139.1m / EBITDA 144.9m)
Debt / FCF = -1.13 (Net Debt -139.1m / FCF TTM 122.9m)
Total Stockholder Equity = 415.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.64% (Net Income 106.0m / Total Assets 777.5m)
RoE = 25.51% (Net Income TTM 106.0m / Total Stockholder Equity 415.6m)
RoCE = 23.03% (EBIT 113.2m / Capital Employed (Equity 415.6m + L.T.Debt 75.9m))
RoIC = 19.38% (NOPAT 82.2m / Invested Capital 424.0m)
WACC = 8.14% (E(4.03b)/V(4.11b) * Re(8.19%) + D(82.8m)/V(4.11b) * Rd(7.75%) * (1-Tc(0.27)))
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.82%
[DCF Debug] Terminal Value 77.22% ; FCFF base≈135.1m ; Y1≈131.9m ; Y5≈132.9m
Fair Price DCF = 48.63 (EV 2.29b - Net Debt -139.1m = Equity 2.43b / Shares 49.9m; r=8.14% [WACC]; 5y FCF grow -3.46% → 2.90% )
EPS Correlation: 6.36 | EPS CAGR: -3.50% | SUE: 0.32 | # QB: 0
Revenue Correlation: 66.19 | Revenue CAGR: 3.89% | SUE: 1.02 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.61 | Chg30d=+0.063 | Revisions Net=+2 | Analysts=3
EPS current Year (2026-12-31): EPS=2.44 | Chg30d=+0.212 | Revisions Net=+3 | Growth EPS=+18.0% | Growth Revenue=+10.2%
EPS next Year (2027-12-31): EPS=2.69 | Chg30d=+0.277 | Revisions Net=+1 | Growth EPS=+10.0% | Growth Revenue=+8.0%